-
HCV Guidance Update – 2022-10-24
This version of the guidance has been updated to reflect several important developments in the identification and management of chronic hepatitis C. Where applicable, all regimens have been reordered by…
-
HCV Guidance Update – 2021-09-29
This version of the guidance has been updated to reflect several important developments in the identification and management of chronic hepatitis C. Sections of the guidance where key updates occurred…
-
HCV Guidance Update – 2021-03-12
This version of the guidance has been updated to reflect several important developments in the identification and management of chronic hepatitis C. Sections of the guidance where key updates occurred…
-
HCV Guidance Update – 2020-08-27
This version of the guidance has been updated to reflect several important developments in the identification and management of chronic hepatitis C. Sections of the guidance where key updates occurred…
-
HCV Guidance Update – 2019-11-06
This version of the guidance has been updated to reflect several important developments in the identification and management of chronic hepatitis C. All treatment sections have been updated; less efficacious,…
-
HCV Guidance Update – 2018-05-24
This version of the guidance has been updated to reflect new testing and management recommendations for pregnant women, people who inject drugs, men who have sex with men, and people who…
-
HCV Guidance Update – 2017-09-21
This version of the guidance has been updated to reflect several important developments, including the recent approvals of glecaprevir/pibrentasvir and sofosbuvir/velpatasvir/voxilaprevir. Updated recommendations reflecting these approvals are provided throughout the…
-
Glecaprevir/pibrentasvir and sofosbuvir/ velpatasvir/voxilaprevir have been approved by the FDA- update coming soon.
In addition to updates for all relevant sections in response to the new approvals, the following new sections will be released soon:
-
HCV Guidance Update – 2017-04-27
This version of the Guidance has been updated to reflect several key developments as indicated below. Updated references have been provided throughout the Guidance. Global Changes Occurring throughout the document:
-
HCV Guidance Update – 2016-09-16
The HCV Guidance Panel has reviewed new information that highlights the risk of HBV infection reactivation in patients who are coinfected and who clear HCV with DAAs. They have therefore…
Explore All Resources
View additional resources related to the HCV Guidance.
